Marika Guercio

Marika Guercio


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 August 2025 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
FLFranco Locatelli
Franco Locatelli
DPDaria Pagliara
Daria Pagliara
MIMaria A. De Ioris
Maria A. De Ioris
MBMarco Becilli
Marco Becilli
GBGiada Del Baldo
Giada Del Baldo
FBFrancesca Del Bufalo
Francesca Del Bufalo

29 March 2024 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
RCRoselia Ciccone
Roselia Ciccone
CQConcetta Quintarelli
Concetta Quintarelli
ACAntonio Camera
Antonio Camera
MPMichele Pezzella
Michele Pezzella
SCSimona Caruso
Simona Caruso
FLFranco Locatelli
Franco Locatelli
Purpose: Medulloblastoma (MB), the most common childhood malignant brain tumor, has a poor prognosis in about 30% of patients. The current standard of care, which includes surgery, radiation, and chemotherapy, is often responsible for cognitive, neurologic, and endocrine side effects. We investigated whether chimeric antigen receptor (CAR) T cells directed toward the disialoganglioside GD2 can represent a potentially more effective treatment with reduced long-term side effects. Experimental Design: GD2 expression was evaluated on primary tumor biopsies of MB children by flow cytometry. GD2 expression in MB cells was also evaluated in response to an EZH2 inhibitor (tazemetostat). In in vitro and in vivo models, GD2+ MB cells were targeted by a CAR-GD2.CD28.4-1BBζ (CAR.GD2)-T construct, including the suicide gene inducible caspase-9. Results: GD2 was expressed in 82.68% of MB tumors. The SHH and G3–G4 subtypes expressed the highest levels of GD2, whereas the WNT subtype expressed the lowest. In in vitro coculture assays, CAR.GD2 T cells were able to kill GD2+ MB cells. Pretreatment with tazemetostat upregulated GD2 expression, sensitizing GD2dimMB cells to CAR.GD2 T cells cytotoxic activity. In orthotopic mouse models of MB, intravenously injected CAR.GD2 T cells significantly controlled tumor growth, prolonging the overall survival of treated mice. Moreover, the dimerizing drug AP1903 was able to cross the murine blood–brain barrier and to eliminate both blood-circulating and tumor-infiltrating CAR.GD2 T cells. Conclusions: Our experimental data indicate the potential efficacy of CAR.GD2 T-cell therapy. A phase I/II clinical trial is ongoing in our center (NCT05298995) to evaluate the safety and therapeutic efficacy of CAR.GD2 therapy in high-risk MB patients.

27 October 2021 in Cells
Verified
Journal Article
Open access
PDF file
FPFederica Pulvirenti
Federica Pulvirenti
ASAne Fernandez Salinas
Ane Fernandez Salinas
Cinzia MilitoCinzia Milito
Cinzia Milito
STSara Terreri
Sara Terreri
EMEva Piano Mortari
Eva Piano Mortari
IQIsabella Quinti
Isabella Quinti
Background: Patients with primary antibody deficiencies are at risk in the current COVID-19 pandemic due to their impaired response to infection and vaccination. Specifically, patients with common variable immunodeficiency (CVID) generated poor spike-specific antibody and T cell responses after immunization. Methods: Thirty-four CVID convalescent patients after SARS-CoV-2 infection, 38 CVID patients immunized with two doses of the BNT162b2 vaccine, and 20 SARS-CoV-2 CVID convalescents later and immunized with BNT162b2 were analyzed for the anti-spike IgG production and the generation of spike-specific memory B cells and T cells. Results: Spike-specific IgG was induced more frequently after infection than after vaccination (82% vs. 34%). The antibody response was boosted in convalescents by vaccination. Although immunized patients generated atypical memory B cells possibly by extra-follicular or incomplete germinal center reactions, convalescents responded to infection by generating spike-specific memory B cells that were improved by the subsequent immunization. Poor spike-specific T cell responses were measured independently from the immunological challenge. Conclusions: SARS-CoV-2 infection primed a more efficient classical memory B cell response, whereas the BNT162b2 vaccine induced non-canonical B cell responses in CVID. Natural infection responses were boosted by subsequent immunization, suggesting the possibility to further stimulate the immune response by additional vaccine doses in CVID.

15 January 2025 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
CQConcetta Quintarelli
Concetta Quintarelli
FBFrancesca Del Bufalo
Francesca Del Bufalo
MIMaria Antonietta De Ioris
Maria Antonietta De Ioris
MGMarika Guercio
Marika Guercio
MAMattia Algeri
Mattia Algeri
FLFranco Locatelli
Franco Locatelli

14 June 2022 in Cells
Verified
Journal Article
Open access
PDF file
FPFederica Pulvirenti
Federica Pulvirenti
SCStefano Di Cecca
Stefano Di Cecca
MSMatilde Sinibaldi
Matilde Sinibaldi
EMEva Piano Mortari
Eva Piano Mortari
STSara Terreri
Sara Terreri
IQIsabella Quinti
Isabella Quinti
Following the third booster dose of the mRNA vaccine, Common Variable Immune Deficiencies (CVID) patients may not produce specific antibodies against the virus spike protein. The T-cell abnormalities associated with the absence of antibodies are still a matter of investigation. Spike-specific IgG and IgA, peripheral T cell subsets, CD40L and cytokine expression, and Spike-specific specific T-cells responses were evaluated in 47 CVID and 26 healthy donors after three doses of BNT162b2 vaccine. Testing was performed two weeks after the third vaccine dose. Thirty-six percent of the patients did not produce anti-SARS-CoV-2 IgG or IgA antibodies. Non responder patients had lower peripheral blood lymphocyte counts, circulating naïve and central memory T-cells, low CD40L expression on the CD4+CD45+RO+ and CD8+CD45+RO+ T-cells, high frequencies of TNFα and IFNγ expressing CD8+ T-cells, and defective release of IFNγ and TNFα following stimulation with Spike peptides. Non responders had a more complex disease phenotype, with higher frequencies of structural lung damage and autoimmunity, especially autoimmune cytopenia. Thirty-five percent of them developed a SARS-CoV-2 infection after immunization in comparison to twenty percent of CVID who responded to immunization with antibodies production. CVID-associated T cell abnormalities contributed to the absence of SARS-CoV-2 specific antibodies after full immunization.

8 September 2025 in Nature Medicine
Verified
Journal Article
Closed access
FLFranco Locatelli
Franco Locatelli
DPDaria Pagliara
Daria Pagliara
MIMaria A. De Ioris
Maria A. De Ioris
MBMarco Becilli
Marco Becilli
GBGiada Del Baldo
Giada Del Baldo
FBFrancesca Del Bufalo
Francesca Del Bufalo